Publication Name	World Journal of Gastroenterology
Manuscript ID	99312
Country	France

Received	2024-08-21 05:55
Peer-Review Started	2024-07-19 09:03
To Make the First Decision
Return for Revision	2024-11-10 03:24
Revised	2024-11-13 11:12
Second Decision	2024-11-20 02:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-20 07:08
Articles in Press	2024-11-20 07:08
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-12-02 01:13
Typeset the Manuscript	2024-12-04 00:05
Publish the Manuscript Online	2024-12-30 06:47

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model
Manuscript Source	Invited Manuscript
All Author List	Luciano Pirola
ORCID	Author(s) ORCID Number Luciano Pirola http://orcid.org/0000-0001-6539-5435
Funding Agency and Grant Number
Corresponding Author	Luciano Pirola, PhD, Carmen Laboratory, INSERM Unit 1060-Lyon 1 University, CENS ELI-2D Building, 165 Chemin du Grand Revoyet, Pierre Benite 69310, France. luciano.pirola@univ-lyon1.fr
Key Words	PPAR nuclear receptors; Elafibranor; Steatotic liver disease; Alcohol associated liver disease; Liver fibrosis
Core Tip	Metabolic dysfunction-associated steatotic liver disease (SLD) needs novel pharmacological treatments elafibranor, a PPAR agonist, remains a promising molecule against SLD caused by alcohol consumption. Koizumi et al, report, using a mouse model of alcohol-associated liver disease, that hepatic steatosis, liver fibrosis and hepatocyte apoptosis are alleviated by administration of elafibranor. These data support the potential beneficial action of elafibranor, warranting clinical testing.
Publish Date	2024-12-30 06:47
Citation	<p>Pirola L. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. <i>World J Gastroenterol</i> 2025; 31(4): 99312</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i4/99312.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i4.99312

Full Article (PDF)	WJG-31-99312-with-cover.pdf
Manuscript File	99312_Auto_Edited_013826.docx
Answering Reviewers	99312-answering-reviewers.pdf
Audio Core Tip	99312-audio.mp3
Conflict-of-Interest Disclosure Form	99312-conflict-of-interest-statement.pdf
Copyright License Agreement	99312-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	99312-non-native-speakers.pdf
Peer-review Report	99312-peer-reviews.pdf
Scientific Misconduct Check	99312-scientific-misconduct-check.png
Scientific Editor Work List	99312-scientific-editor-work-list.pdf
CrossCheck Report	99312-crosscheck-report.pdf